Research expertises profiled and compared. Find experts in Biotechnology, Translational, Basic Biology, Drug Discovery, Plant Biology, Biomedical Engineering, Molecular Biosciences fast! We aim to introduce autonomous infrastructure for Life Science arranging information on available academic research labs and their research outputs and keeping it on one platform. Bio Consulted by A-LabInsider aggregates information on Life Science labs to help scientists to find partners for grant proposals, get information on research in competitor labs, find and compare labs for job positions, be noticed by Pharma companies for grants and events, and be eligible for better deals on lab devices and reagents. The company works with Pharma, Biotech and academia as well as publishers and funding bodies.
ACellT (Apeiron Cell Therapies) is a newly founded clinical-stage entity, focused on Cell Therapy development. The company was founded with the checkpoint inhibitor asset APN401 from APEIRON Biologics AG. The project is a master checkpoint inhibitor cbl-b (first-in-class) ambulatory autologous cell therapy (first-in-platform).
Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate is Adrecizumab, a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials. https://adrenomed.com/
Alpha Tau Medical Ltd.
Alpha Tau is an Israeli clinical stage company that has developed the first alpha radiation-based cancer treatment for numerous types of solid tumors: the Alpha DaRT.
Alpha DaRT enables alpha radiation for the local treatment of solid tumors by releasing short-lived alpha-emitting atoms in the tumor, overcoming the traditional limitation of alpha radiation’s short therapeutic range, and achieving the holy grail of delivering a high dose of radiation inside the tumor while sparing surrounding healthy tissue.
Alpha DaRT has demonstrated success in controlled destruction of multiple tumor types, with >10 years of pre-clinical research generating 14 published peer-reviewed studies. The studies have also demonstrated signs of triggering a broader immune system effect and potential boost to immunotherapy treatments.
In our first human clinical trial, the Company demonstrated 100% overall response rate and 79% complete response in treating difficult SCC tumors (primarily radioresistant or recurrent) within days, with no systemic and/or serious side-effects and low toxicity.
The Company is currently conducting multiple clinical trials across indications at leading cancer centers across the world, with trials set to start in the next few weeks in skin cancer at Memorial Sloan Kettering Cancer Center and pancreatic cancer at University of Montreal Health Center (CHUM). https://www.alphatau.com/
AMRYT PHARMA PLC. [LON: AMYT]
Amryt is a commercial-stage biopharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt comprises a strong and growing portfolio of commercial and development assets. Amryt two commercial products are: • Juxtapid®/ Lojuxta® (lomitapide) • Myalept® / Myalepta® (metreleptin) Amryt's lead development asset AP101 (Oleogel-S10), is a potential treatment for the cutaneous manifestations of Epidermolysis Bullosa ("EB"). AP103 is a pre-clinical gene-therapy platform technology which offers a potential treatment for patients with Recessive Dystrophic Epidermolysis Bullosa, a subset of EB, and is also potentially relevant to other genetic disorders. https://www.amrytpharma.com/
Anagenesis Biotechnologies is a private company developing new treatments against muscle diseases (genetic such as Duchenne Muscular Dystrophy (DMD) and chronic such as sarcopenia and cachexia). The company was cofounded by Prof. Olivier Pourquié, a worldwide key opinion leader in the field of musculoskeletal development and stem cells. Olivier Pourquié is a Professor at Harvard Medical School and the Brigham and Women’s Hospital and a member of the Harvard Stem Cell Institute. Anagenesis Biotechnologies is backed by a solid, experienced team led by its President & CEO, Dr. Jean-Yves Bonnefoy, coming from the Pharma & Biotech industry. For more information, please visit www.anagenesis-biotech.com. Anagenesis Biotechnologies’ proprietary Paraxial Mesoderm Multipotent Cells (P2MCs) technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into skeletal muscle, brown fat, dermis, endothelial cells, cartilage and bone. The P2MC technology was developed with the support of AFM-telethon, INSERM, CNRS and Université de Strasbourg.
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.
Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors), Huntington's disease (monitoring mutant Huntingtin translation pausing) and Repeat Associated Diseases (translation malfunctions).
Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations. https://www.animabiotech.com/
Anocca is a biotechnology company developing next-generation immunotherapies via individualisation of therapeutic products to precisely leverage the immune system of each patient.
Due to both the immense complexity of immunity and the significant differences in the composition of the immune system between individuals, there is a need to individualise targeted immunotherapeutics. Anocca’s unique technology platform captures key information from the immune system of each individual to deliver a range of immunotherapies specifically tailored to target the disease attributes of each patient, and to work safely within the constraints of each patient’s immune system.
Anocca’s first clinical programs aim to deliver cellular therapies equipped either with targeting receptors from our receptor libraries that are tailored for defined groups of individuals, or equipped with targeting receptors that are created for each patient in a fully individualised manner.
ariadne-service gmbh is a Swiss company dedicated to high-throughput biomedical image analysis. Our multidisciplinary team of neuroscientists and machine-learning experts combines human and artificial intelligence to turn terabytes of histopathological microscopy data of cell cultures and neural tissue into quantitative results. We develop and offer cutting-edge image processing technology - scalable in throughput, consistent in quality. Among our newest products is LMtrace®, a versatile biomarker for neurological diseases that is based on neuron shape analysis. LMtrace® is going to reduce the failure rates for neuron-based drug screening assays tremendously and will revolutionize drug discovery for brain diseases such as Alzheimer’s or Parkinson’s and neurotoxicological screens. https://ariadne.ai/
ARTIDIS AG is a spinoff from the Biozentrum, University of Basel, Switzerland that has developed the first nanomechanical biomarker for cancer diagnosis and treatment optimization. ARTIDIS nanotechnology platform integrates different types of clinical data into the ARTIDISNet digital platform, allowing physicians to significantly shorten the current diagnostic process and bringing benefit to both the patient and the healthcare system. ARTIDIS enables professionals to design personalized cancer treatment plans tailored to the individual patient needs and desired outcomes.
Atara Biotherapeutics, Inc. (@Atarabio) is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Atara’s technology platform leverages research collaborations with leading academic institutions with the Company’s scientific, clinical, regulatory and manufacturing expertise. Atara’s pipeline includes tab-cel® (tabelecleucel), which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) as well as in earlier stage development for other EBV-associated hematologic malignancies and solid tumors, including nasopharyngeal carcinoma (NPC); T-cell immunotherapies targeting EBV antigens believed to be important for the potential treatment of multiple sclerosis; and next-generation chimeric antigen receptor T-cell (CAR T) immunotherapies. The Company was founded in 2012 and is co-located in South San Francisco and Southern California. Our Southern California hub is anchored by the state-of-the-art Atara T-cell Operations and Manufacturing (ATOM) facility in Thousand Oaks, California.
AUM Biosciences is founded by industry veterans who have a track record of executing a $120M PE deal to support pharmaceutical giant Eisai leading to the global commercialization of 3 major blockbusters, most recent being Levatinib (Lenvima) for 1st line treatment of liver cancer. This unique model resulted in superior returns of >5X ROI per molecule. This lucrative business model and a strong interdisciplinary team are the core pillars of AUM Biosciences. AUM’s mission is to revolutionize the existing inefficient drug development paradigm by becoming an ecosystem of decentralized R&D innovations. The current centralized R&D model has proven to be unsustainable in the last decade to meet Asia’s growing cancer populations need. We are disrupting this space by employing a unique multifaceted holistic approach that involves acquiring (1) First-in-class oncology small molecules from respected organizations and leveraging (2) AI technologies and (3) Mandatory biomarker utilization to accelerate drug development through proof of concept. This allows us to build a sustainable IP infrastructure of continuous data-driven innovations that can be shared across the 3 business segments. We have acquired global rights in all indications for 2 first-in-class cancer drugs, which is addressing significant unmet medical need in colorectal cancer and PIK3CA mutation bearing cancer types. The lead program has entered phase I with data readout expected in June 2020. We aim to raise our Series A to broaden our portfolio for combinatorial therapies, up-scale our digital technology capabilities and roll out our AI platform while moving our first drug asset to POC to achieve maximum value inflection.
Avectas is a cell engineering business developing a unique delivery technology platform to enable the ex-vivo manufacture of our partners' gene-modified cell therapy products, which will retain high in-vivo functionality. Our vision is to be the leading non-viral cell engineering technology provider, integrated into manufacturing processes for multiple autologous and allogeneic therapies. Avectas’ technology, Solupore®, delivers advanced molecules such as mRNA, proteins and gene editing tools to a range of primary cell types including T cells for immuno-oncology and gene editing applications.
BAYOOMED is your partner for the engineering of medical apps and medical software. With more than 250 person years of project experience, BAYOOMED is highly professional in the regulated CE & FDA environment. We support more than 800 medical and pharma companies and are among the most experienced medical software developers in Europe.
We engineer MHEALTH / EHEALTH applications under iOS (iPhone & iPad) and Android according to IEC 62304 and support product developers and innovators from the pharmaceutical and medical technology sectors in all phases of software product lifecycle. Our Quality management processes certified by TÜV Hessen according to ISO 13485 are a testament to our passion for sustainable solutions and distinct customer focus.
Bone Therapeutics is a listed, clinical-stage, orthopaedic biotech company committed to rebuilding lives of patients suffering from debilitating bone and joint conditions.
Leveraging its extensive expertise in bone physiology and patented manufacturing technology, Bone Therapeutics is developing a unique, commercially ready, allogeneic bone cell therapy platform, ALLOB, and an off-the-shelf protein solution for osteoarthritis pain, JTA-004, which are designed to offer patients and physicians best-in-class treatment options, superior to existing orthopaedic care.
In Phase II-III clinical development, Bone Therapeutics’ advanced product portfolio targets large orthopaedic conditions with high unmet needs, such as knee osteoarthritis, unhealed fractures and spinal fusion.
Boston Pharmaceuticals is a translational drug development company. It was founded in 2016 by Chris Viehbacher, ex-CEO of Sanofi and Rob Armstrong, ex-R&D Executive from Eli Lilly. With $600M committed capital from Gurnet Point Capital, Boston Pharma’s business model is focused on partnering and developing therapeutics from late pre-clinical to clinical POC. In the past 3 years, we have built an experienced clinical development team and acquired a diverse portfolio of fifteen programs in oncology, autoimmune, cardiovascular, dermatology, anti-infective, gastrointestinal, and metabolic, including recent deals with GSK, Novartis, and other Pharma and biotech partners. In principle, we are agnostic with regards to indication or molecular modality. During this conference, we are seeking in licensing and out licensing partnering discussions. https://www.bostonpharmaceuticals.com/
Cergentis is a privately held genomics company based in Utrecht, The Netherlands with the mission to improve the quality of genetic research and human healthcare. We provide services and kits based on our proprietary Targeted Locus Amplification (TLA) technology to leading diagnostic labs, research institutes and pharmaceutical companies worldwide. In short, TLA enables rapid, cost-effective, complete next generation sequencing of genes of interest and provides critical advantages in genetic (cancer) research and diagnostics.
Born and brought up in France, Clingroup celebrates this year its 18 years anniversary , pioneering health and life sciences industry solutions partnering in the EMEA region, from product conception till post marketing and maintenance, including R&D support, Quality and validation, professional development and capacity building, data, big data and e-heath solutions, patient and market access. This is thanks to our customers partners trusts from all health industry and academy along with international organisations collaboration. additionally we have developed privileged partnerships with medical communities of high disease prevalence to facilitate access to patients and research focused ecosystem. With all recognition and achievements, what remains the dearest to our heart is that we are fully dedicated to social responsibility, with all our profits and expertise, we are committed to serving important causes such as children and women health, infectious and liver diseases, children education and poverty, and women empowerment. Partnering with us you will find quality and credibility but also you will feel satisfied of the community improvements impacts of your projects. thank you for your trust and interest.
Domain Therapeutics is a biopharmaceutical company dedicated to the discovery and early development of new drug candidates targeting transmembrane receptors, in particular, G Protein-Coupled Receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops candidates (allosteric modulators and biased ligands) through its innovative approach and technologies. Domain has three revenue-generating pillars within its innovative business model: 1) collaboration with pharma companies for the discovery of new molecules 2) out-licensing of its bioSens-All™ technology and 3) creation of asset-centric vehicles for the development of its internal pipeline of preclinical candidates for central nervous system disorders, cancer and rare diseases. These asset-centric companies attract investment for focused development and exit is through a trade sale at an appropriate inflection point.
Genclis is a private-held biotechnology that discovers "Transcription Infidelity", a unique biological mechanism that produces RNA transcripts that differ from their originating DNA sequence. This mechanism explains the nonrandom occurrence of RNA to DNA divergences (RDD) that lead to translated proteins with sequences diverging from the canonical form . Genclis applies its articifical intelligence platform to extract from large genomic data sets, these low intensity signals. Genclis has shown , in both human and animal models, that specific RDD events shape selectivity the repertoire of natural immunoglobulins that contribute to both allergy and other immunological disorders. Genclis has developed a diversified pipeline of disruptive diagnostic and therapeutic solutions that have and are completing pre-clinical evaluation. Genclis's objectives are to further expand commercial activities in both human , veterinary markets as well as in the food and cosmetic industry while relentlessly pursuing developments of several other novel disruptive pre-clinical assets.
GeneLook is a platform that allows rare disease patients identify, extract and share with the pharmaceutical industry the genetic mutations within their DNA that makes them sick. GeneLook enables rare disease patients form groups based on their specific diseases to give them a stronger voice and advocate for themselves. We expect solving the needs of 400 Million rare disease patients worldwide actively engaged to solving their unmet healthcare needs.
-Patients worldwide can form virtual groups based on genetic variant specificity. -Data sharing is secure, anonymous and instantaneous. -GeneLook accelerates patient recruitment for clinical trials. -The high engagement of rare disease patients on social media will lead to faster adoption of our solution. -Patients get delivered value-based engagement with our mobile App, even from remote locations lacking genetic expertises.
HalioDx is an immuno-oncology diagnostic company providing oncologists and Biopharma with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immuno-oncology and combination therapies.
Immunoscore® proprietary technology, pioneered by Jérôme Galon at the Cordeliers Research Center, Paris, France, integrates immunohistochemistry combined with sophisticated algorithm and advanced imaging analysis enabling extraction of spatially organised tissue molecular information.
Immunoscore® is available Internationally as a CLIA or CE marked test to guide day to day oncologists’ decisions. Immunoscore® is a platform for many cancers, as immune response to tumor is a key hallmark of disease progression. https://www.haliodx.com/
Hi-D Imaging AG
Every person has a unique anatomy but why are they treated the same? Every 4th patient with a heart valve implantation needs either to be re-operated or needs to take life-long medication. Hi-D Imaging AG, an ETH Spinoff company, provides precision medicine to cardiologists, which allows defining the optimum heart valve and the best implementation location for each individual patient. The novel in-vitro heart valve selection tool developed by Hi-D Imaging is based on additive manufacturing, optical imaging and fluid dynamics. The novel pre-operational planning tool (1) provides patient-tailored therapy; (2) increases success rate of the aortic valve replacement; (3) increases patient’s quality of life; and (4) optimizes the design of the next generation heart valves. They are the world’s first company monitoring time-resolved 3D turbulent blood flow patterns in the human heart and use this information for personalized therapy for patients. To date, there is no other company measuring turbulence in the heart in-vitro, presenting a personalized selection tool that can identify the optimal heart valve for patients and enabling the physician to choose a heart valve that fits the anatomy of the patients. Currently, the heart valve is being chosen based on qualitative medical imaging results and the experience of the cardiologists. They are revolutionizing the cardiovascular treatment by making personalized heart valve replacement therapy a reality. Hi-D Imaging is a multidisciplinary family. Their team is a great fusion of engineers, experimentalists, data analysists, and clinicians. Their aim is to bring their novel technology to as many as patients all around the world. http://www.hidimaging.com/
IGEM Therapeutics Ltd.
A UK-based Immuno-Oncology company focused on the development of IgE antibody drugs to fight cancer. IgE has evolved to kill parasites which reside in human tissue, also the home of the solid tumour. The company has shown that IgE has specific properties that allow it to outperform IgG antibody equivalents in pre-clinical testing.
The company’s lead product candidate, IGEM-F*, is in a Phase 1/2a clinical trial in ovarian cancer patients. This is the world’s first IgE drug to enter clinical trials. IGEM has constructed a novel and proprietary pipeline of anti-cancer IgE antibodies.
LiMM is the biopharmaceutical company harnessing the molecular cross-talk between neuronal and innate lymphoid cells within peripheral tissues. By decoding the language of the neuroimmune cross-talk, we are developing first-in-class therapeutic products – NRILs: neuronal reprogrammers of innate lymphocytes - to preserve health and treat inflammatory, infectious and metabolic diseases. We are bridging neural sensing and immunology discoveries to unlock therapeutic solutions for the benefit of patients.
MedinCell is a clinical stage pharmaceutical company developing long acting injectables with BEPO®, its game-changing technology platform enabling controlled, localized and sustained drug delivery. MedinCell develop a portfolio of best-in-class medicines incorporating additional benefits related to therapeutic compliance, targeted action and ease of use. Listed on Euronext Paris since October 2018.
Metys Pharmaceuticals AG is developing a pipeline of newly-patented non-racemic mixtures of orally active, CNS-penetrant small molecule drug candidates in Phase 2 and in preclinical development. The lead candidate, MP-101, is prepared for Phase 2 clinical trials for the treatment and prevention of symptoms of peripheral neuropathy; while MP-102 is a pre-clinical development candidate for the oral treatment of tonic seizures and epilepsy. MP-103 is also a pre-clinical development candidate for treatment-resistant depression. MP-101, MP-102, and MP-103 consist each of a non-racemic mixture of its enantiomers, and are protected by new composition-of-matter patent claims for these unusual mixtures.
Microbiotica is founded on ground-breaking microbiome science from the Wellcome Sanger Institute. The company has unique capabilities to isolate all gut bacteria from any human and to identify gut bacterial signatures linked to patient phenotype from large clinical datasets with unprecedented precision. It is initially progressing live bacterial therapeutics and biomarkers in IBD and I-O, driven by best-in-class clinical datasets. The company has a $534m commercial partnership with Genentech, and clinical collaborations with Univ of Adelaide, Cambridge University Hospitals and Cancer Research UK.
NEURILIV THERAPEUTICS is a clinical stage startup, spin-off of adMAre Bioinnovations. We are developing a unique "modality-selective" TRPV1 antagonist against Neuropathic Pain. Results of a phase I SAD revealed that, unlike previously clinically tested TRPV1 antagonists, NRV6860 does not induce hyperthermia or impaired noxious heat perception in humans, while reducing the area of secondary hyperalgesia provoked by intradermal capsaicin injections in human volunteers. We are seeking financing to complete a phase I MAD and a phase II clinical proof of concept.
We design and develop a new class of powerful therapeutics for the treatment of severe diseases. Our plug-and-play platform substantially reduces the random nature of the discovery process to predictably yield ready-to-develop multispecific biotherapeutics for chronic inflammation and cancer.
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.
From its founding in 2000 through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases. Our business model is to develop our proprietary drug candidates through clinical phase II, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization.
Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional Pipes in 2017 (€18.2M), 2018 (€13M) and 2019 (€20M), where the company incorporated specialized investors from US and Europe.
The company has a broad and growing portfolio, with two compounds in clinical trials, iadademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIa in oncology, and vafidemstat (ORY-2001), a CNS optimized LSD1 inhibitor in Phase IIa for the treatment of neurological diseases;, as well as another compound in preclinical development, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional programs in other cancer indications.
From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program, iadademstat, and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of vafidemstat since the start of our CNS research. https://www.oryzon.com/
Founded in 2017 and based in Israel, Pantheon Biosciences is an early-stage biotechnology company committed to harnessing the immense diversity of bacterial immunity into revolutionary biomedical platforms and therapeutics. We are leveraging unexploited insights hidden in bacterial defense systems to develop innovative antiviral drugs and next-generation therapeutics for molecular engineering. Driven by cutting-edge research from Prof. Rotem Sorek of The Weizmann Institute of Science, we progress two Pantheon’s proprietary novel antiviral small molecules into INDs, creating a broad product portfolio derived from the novel bacterial defense systems.
Founded in April 2014 as a spin-off of the French Blood Bank (Etablissement Français du Sang, EFS), PDC*line Pharma is a Belgian-French biotech company that is developing a novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) pre-loaded with peptides that are derived from target tumor antigens. Based on a robust preclinical package and a first-in-human phase Ib feasibility study in melanoma, PDC*line Pharma is focusing on lung cancer with a new candidate in phase 1b/2 clinical trial (PDC*lung) and neoantigens (PDC*Neo).
PDC*line Pharma comprises a team of highly skilled professionals based in Liège (Belgium) and Grenoble (France). PDC*line Pharma has raised nearly €30 M in equity and non-dilutive funding.
In January 2019, PDC*line Pharma has been GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control & Release Activities for PDC*lung, a drug for lung cancer immunotherapy.
In march 2019, PDC*line Pharma granted exclusive license in South Korea and exclusive option in other Asian countriesto LG Chem Life Sciences Company, for the development and commercialization of PDC*lung cancer vaccine for lung cancer. The total deal value is 123M$ plus significant tiered royalties on net sales in Asia.
In May 2019, PDC*line Pharma obtains authorization to launch phase I/II trial of its cancer vaccine (PDC*lung01) in non-small cell lung cancer. The Belgian Federal Agency for Medicines Health Product (FAMHP), together with the designated Ethics Committee, authorized the initiation of an open-label, dose-escalation, phase I/II trial with the cancer vaccine candidate (PDC*lung01) for non-small-cell lung cancer. https://www.pdc-line-pharma.com/
Phi Pharma S.A.
Phi Pharma S.A. is a private Switzerland-based biotech company focusing on the development of innovative targeted medicines for the treatment of cancer.
We use a proprietary, patent protected technology platform to develop highly specific and effective Peptide Drug Conjugates (PDCs) for the treatment of liquid (our imminent focus) and solid tumours.
Our pipeline currently comprises 3 development programs, including an IVD companion diagnostic for patient stratification.
Our invention and key differentiating achievement relates to the novel oncology target class of GAGs, in particular to C-4-S, over-expressed on tumour cells, addressing various cancers with major unmet medical need.
Our technology allows the development of a powerful new class of Peptide Drug Conjugates which have the potential to overcome the limitations of Antibody Drug Conjugates.
Phi Pharma’s technology is based on the ground-breaking discovery of HIV using TAT peptide to penetrate white blood cells to deliver its deadly cargo. Naturally occurring TAT peptide has a very short half-life in blood as it is being instantly degraded by respective enzymes.
By super-computer assisted modelling Phi Pharma was able to identify, synthesize and patent protect “semi-synthetic” TAT-derived peptides with dramatically improved stability and affinity, hence targeting properties.
After extensive in-vitro, ex-vivo and in-vivo work, Phi Pharma is now completing the in-vivo PoC package and preparing the pre-clinical development of the lead compounds to move towards IND-readiness and the implementation of a first in human PoC phase 1/2a clinical trial.
The experienced Management Team plans to reach FIH clinical stage within less than 24 months and PoC in Human within only 36 months. https://www.phi-pharma.com/
A venture-backed biotech company with programmes focused on global health and innovation including vaccines against enter fever, Chlamydia trachomatis and Yersinia pestis, the latter being developed with the UK government. The synthetic biology platform, which has been safely tested in 10 clinical trials in 351 volunteers, is also being evaluated as a microbial immunotherapy targeting technology for solid tumours. Prokarium is based at the London Bioscience Innovation Centre near St Pancras station in Central London. We are always looking to connect with ambitious scientists and advisors within Synthetic Biology/Molecular Biology and Immunology & Oncology.
SciRhom GmbH, based in IZB Martinsried, Germany, is a biotech start-up company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening diseases. Improving autoimmune disease therapies is the central aspiration of SciRhom. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in late 2016 through a collaboration between scientists from academia and scientists with profound experience in antibody development. To date, we have secured about EUR 7 million in seed funding from the High-Tech Gruenderfonds (HTGF), private investors and the Hospital for Special Surgery (HSS) in New York, USA, one of the world’s top-ranking academic medical centers in Rheumatology and musculoskeletal health.
STALICLA is a Biotech Company developing a first-in-class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDDs). STALICLA is using computational systems biology tools to characterize correlations between NDD phenotypes, gene expression in relevant molecular pathways and treatment response. First focus of development has been Autism Spectrum Disorder (ASD). Today, patients diagnosed with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need. In its Geneva and Barcelona units, STALICLA has assembled a world-class team of drug developers and computational biologists. The Company is recognized as a disruptive player, using its DEPIv3 innovative AI platform. DEPIv3 integrates domain specific large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and to identify personalized treatments. It is the first time that such technologies have been utilized within for NDDs with the potential to change the direction of the specialty. DEPIv3 has already proven successful in expediting and de-risking drug development for a first subgroup of patients with Autism and identifying two additional subgroups. STALICLA’s first therapeutic package - STP1 - addresses this first distinct subgroup of ASD patients - ASD Phenotype 1- estimated to 1.5 - 2M people in the EU and North America. Clinical entry for STP1 is planned in Q1 2020. ASD Phenotype 1 patient cells have been characterized at molecular level, revealing a ‘fingerprint’ specific to this subgroup of patients with ASD and allowing the development of a Companion Diagnostic tool. To support its platform and pipeline development, STALICLA has developed a network of top-tier research and clinical partners in the US. This has enabled STALICLA to gather one of the largest Autism patients Electronic Health Records database to date. STALICLA is currently scaling up DEPIv3 to advance new pipelines for additional groups of patients with NDDs.
Starpharma Holdings Limited, located in Melbourne Australia, is an ASX 300 company and is a world leader in the development of dendrimer products for pharmaceutical and life science applications.
Starpharma’s underlying technology is built around polylysine dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical and medical uses. Starpharma has two core development portfolios: VivaGel® portfolio and DEP® drug delivery with the Company developing several products internally and others via commercial partnerships e.g. AstraZeneca, which allows an accelerated path to market and management of investment risk.
Unicyte AG is a regenerative medicine biotech company focusing on liver & kidney disorders, diabetes, and oncology. Unicyte is developing three major technology platforms, including a pioneering approach harnessing extracellular vesicles, in a long-term collaboration with the University of Turin. In 2019, Unicyte raised €60mn (Series A) for clinical development.
VAXIMM is a privately held, clinical stage, Swiss/German biotech company developing oral T-cell immunotherapies for patients suffering from cancer. VAXIMM’s technology is based on first-in-class oral T-cell activators using modified attenuated bacteria that can be readily adapted to target a wide range of cancer-related antigens. The most advanced product candidate VXM01 is currently in clinical development for several tumor types including brain cancer, in combination with the anti-PD-L1 checkpoint Inhibitor avelumab. VAXIMM also has a neoantigen program currently in preparation for entering clinical phase 1; the Company’s platform allows for fast generation and delivery of personalized T-cell cancer vaccines and may overcome key issues faced by other neoantigen approaches.